Colorectal cancer, regulatory T cells and S1P signaling
Colorectal cancer is the second leading cause of cancer death in the United States [44] . Approximately 15% of all colorectal cancers are related to one of the two inherited forms: Familial Adenomatous Polyposis (FAP), which is caused by a mutation in the adenomatous polyposis coli (APC) gene and Hereditary Nonpolyposis Colorectal Cancer (HNPCC) which is caused by mutation in any of the DNA mismatch repair protein such as: the msh2 gene, Mut homolog 1, mlh1 gene, or hMSH2 gene [45] [46] [47] [48] [49] . Other sporadic colorectal carcinomas have been linked to mutations in p53 genes, K-ras, SMAD4, 18q21 allelic loss associated with or without chromosomal or microsatellite instabilities [50] . Numerous studies have indicated that inheritance of the mutated APC gene is not sufficient to cause colorectal cancer; additional genetic alterations or environmental changes are required for tumor formation [51] . In a murine model of APC mutation known as Min mice, the development of polyps, a precursor to CRC development in these mice, is influenced by a mutation in the Mom1 (modifier of Min) gene. Mom1 encodes for a secreted phospholipase, A2, which catalyzes the formation of arachidonic acid, an important mediator of inflammation. Indeed, Min mice with mutated Mom1 gene were shown to have lower polyp and tumor numbers [52, 53] . These data suggest that the microenvironment affects polyp development and may genetically and epigenetically alter tumor cell growth in inflamed/immune environments [54] . Collectively, these data established that multiple mutations are necessary for colorectal cancer development, and that inflammation is an important environmental factor modifying gene mutations and tumorigenesis.
The function of FoxP3+ Tregs in colorectal cancer is paradoxical. On one hand, a high density of FoxP3+ Tregs in tumors is associated with a good prognosis [55, 56] . As a strong correlation has been shown between inflammation and CRC outcomes [57, 58] and when Treg function is to suppress the inflammatory response, CRC tumorigenesis develops slower and the prognosis is most likely be more favorable. However, other studies have shown that FoxP3+ Tregs favor colon tumor growth [59, 60, 61] consistent with reports in other tumors such as breast cancer and hepatocellular carcinoma where increased numbers of Tregs correlate with reduced overall survival [62] [63] [64] [65] . This is particularly true if Treg function is to suppress effective T cells involved in immuno-surveillance. Tregs may promote tumorigenesis by suppressing the Th1 antitumorigenic response or by interfering with the inhibitory function of cytotoxic T cells [56, 66] . An important distinction should be noted, however, between CRC and other epithelial cancers. In many solid tumors, infiltrating T lymphocytes have specificity for tumor-specific antigens or self-antigens that allow them to destroy cancer cells [67, 68] . In the case of CRC, in addition to cytotoxic CD8+ T with specificity to tumor antigens, there are many inflammatory T cells with specificity to the commensal miroflora [69, 70] which could affect the functions of Tregs and cytotoxic T lymphocytes. These data add to the complexity of our understanding of the roles of Tregs in CRC.
As such, direct analysis of Tregs in tumors may not be a reliable biomarker for prognosis of CRC [71] [72] [73] [74] . Instead, others have examined the ratio of CD3+ or CD4+ to FoxP3+ Tregs and have determined that this may be a better predictor of clinical outcome in patients with colon carcinoma [75, 76, 77] . Yet, there are still many facets to Tregs, CRC, and tumor progression that have not been explored in detail. Recent identification of a subtype of Tregs in a mouse model and in some human colon cancer helps to explain the paradoxical functions of these cells [78] . One differentiating factor between distinctive Tregs is the expression of RAR-related orphan receptors (ROR)-t, which have previously been shown to be vital for Th17 differentiation [79] (Figure 1 ). Th17 cells were shown to preferentially express IL17, IL-17F and IL-22, and induce inflammation [79] . Using APC  mice containing a mutation leading to a loss of APC function that develops benign adenomatous polyps, Blatner et al. [78] While many Tregs are observed in CRC [75, 77, 80] , little is known about the mechanism regulating their entry into CRC, though cytokine-mediated regulation of Tregs in inflammation has been suggested [81] . Recently, several chemokine-signaling axes have been shown to mediate Treg recruitment to inflamed sites and tumors [82, 83] . In addition to G protein coupled receptor (GPCR) chemokine receptors, sphingosine-1 phosphate receptors (S1P 1 -S1P 5 ) are also important regulators of immune cells including Tregs [84, 85, 86] . Of the five S1P signaling receptors, signaling from S1P 1 is most studied and has been shown to regulate immune cell migration and activation of specific T cell subsets [87, 88] . S1P, the agonist of these receptors, is a sphingolipid that is formed from sphingosine, a product of ceramide degradation, by two known sphingosine kinases SphK1 and SphK2 [89, 90, 91] . S1P and S1P 1 regulating the differentiation of Th2, Tregs, Th17 and to some extent Th1 cells have been shown [88] . Moreover, experiments using transgenic mice carrying CD4+ T cells overexpressing S1P 1 provides a first clue that this pathway may regulate Treg recruitment in extrathymic tissues [92] . The S1P 1 transgenic mice expressed high level of IL-4, an important cytokine required for the selective development of CD4+ CD25+ Tregs [86] ; thus, high numbers of CD4+CD25+FoxP3+ Tregs were observed in S1P 1 transgenic compared to wild type mice [86] .
More recent studies, have shown that S1P 1 signaling restrains thymic Treg development, affects their peripheral numbers, and inhibits Treg suppressive functions by interfering with the function of TGF- [87, 93] . Using transgenic mice with Treg overexpression of S1P 1 signaling or transgenic mice with S1P 1 ablation in T cells, Liu et al. demonstrated S1P 1 signaling controls T cell lineage specification [94] . A reduced number of Tregs were observed in the lymphoid tissues and in the colon of mice with T cells over expressing S1P 1 while Th1 subset was increased in the same mice [94] . Interestingly, another group had reported that there was an increase of Tregs in the periphery of S1P 1 -transgenic mice [92] . The discrepancy between these data may be due to the pleiotropic that blocking this signaling pathway inhibits tumor progression [99] . However, whether S1P 1 regulates Treg development or their function in the inflamed environment remains to be determined. We observed a reciprocal relationship between S1P signaling (tumor progression) and the Treg population [99] . Interestingly, in a recent study published by Liang et al. [100] using SphK2 −/− mice (one of the two kinases responsible for making S1P) in a colitis associated colon cancer model, SphK2
−/− mice, exhibited severe inflammation and developed larger tumors in greater numbers after AOM/DSS treatment. The phenotype was shown to be due to a compensatory mechanism of upregulation of SphK1 after the loss of SphK2. The group also used FTY720 (Fingolimod), a prodrug that is converted to the active FTY720-P form, to down regulate S1P 1 signaling and demonstrated that FTY720 alleviates colitis reducing tumor size and number [100] . While the group did not report on the effect of FTY720 on Treg development, others have shown that FTY720 induces activation of CD4+CD25+ Tregs [94, 103] . These findings suggest that modulation of S1P 1 /IL6/STAT3 signaling in transformed/cancer cells or in immune cells, including Tregs, may affect the tumor microenvironment and thereby alter CRC tumor progression.
Therapeutic strategies targeting Tregs and S1P in CRC
Among many immune cells recruited to the CRC tumor site, Tregs appear to orchestrate the immune reaction that affects clinical outcomes. In light of Blatner's data [78] , the identification of ROR-t+ Tregs provides a new immnunotherapy targeting Tregs. An important consideration should be noted in regards to the time of Treg recruitment during tumor development. Tregs which are ROR-t-tend to arrive at tumor site very early during the inflammation [104] . These Tregs have specificity to the non-self-antigen and would most likely function in controlling inflammation [35] . High number of ROR-t-Tregs, especially during early stage of tumor development, may indicate a good prognosis. This hypothesis is consistent with the findings that treatment targeted inflammatory response in CRC would have a positive clinical outcome [105] . As such, in a recent retrospective study of over 900 patients, those with colorectal cancer on a regular regimen of aspirin were significantly likely to have reduced mortality rates [105] . This study demonstrates the crucial role of inflammation, especially the interaction between inflammation and tumor progression, and the benefit of controlling some CRCs at the early stage with anti inflammatory drugs.
As a tumor progresses, ROR-t+ Tregs were shown to be pro-tumorigenic since they suppress the cytotoxic T cells. Drugs targeting the ROR receptor to interfere with the function of ROR-t+ Tregs would most likely alter disease progression. Along this line, drugs that target the S1P pathway to prevent Tregs as well as other lymphocyte egression from the lymph nodes are especially important. In our recent paper, we demonstrated that the S1P pathway is associated with IL-6 signaling pathway which maintains the persistently activated STAT3 and sphingosine kinases in tumor cells. The cycle between S1P, immune cell recruitment, IL-6, activated STAT3 and sphingosine kinases and S1P is required for tumor progression and has been demonstrated by other groups [100, 101] . Interestingly, we observed that the epithelial STAT3 status in tumor cells correlated with the reciprocal Treg population in the tumor environment of colitis associated CRC; while conditional knock-out mice of epithelial STAT3 showed a significantly higher CD4+CD25+ Tregs [99] . We advocate the usage of FTY720 as well as other classes of drugs to perturb the S1P metabolism in treatment of late stage CRC [106] .
Understanding the mechanisms by which Tregs mediated immune suppression would help in designing more appropriate drugs to inhibit Treg activity. As mentioned previously, Tregs mediate the suppression of effective T cells by direct contact via CTLA4. Antibodies targeting the interaction between CTLA4 and CD80 have been developed to inhibit the suppression function of Tregs on cytotoxic T cells; thereby allowing those cells to destroy tumors [107, 108, 109] . In an animal model of colitis using adoptively transferred of CD4+CD25− T cells into SCID mice infected with the protozoan parasite Leishmania, transferring CD4+CD25+ T cells can reverse colitis. The effect of CD4+CD25+ was blocked if anti-CTLA4 antibody was used [110] . These data suggest that antibody against CTLA4 can block the function of Tregs. Antibodies against CD25 targeting Tregs have also been used to improve immunotherapy responses in cancer [111, 112] . In short, different modalities targeting Tregs in CRC should be considered as an additional strategy to the current treatment options.
Conclusion
Since the discovery of FoxP3+, many subsets of regulatory T cells have been identified. Their main function is to suppress the immune system thus preventing the innate and adaptive immune responses from going awry. Functions of Tregs in CRC are beginning to unfold with the identification of non-pathological and pathological Tregs (ROR-t+). Understanding the development of these cells is pivotal in CRC treatment. Several mechanisms have been proposed for their presence in CRC: 1) they could represent pre-existing Tregs 2) arise from CD4+ effective cells and 3) be recruited from natural Tregs. The general consensus of pathological Tregs in CRC is pro-tumorigenic since they suppress immunosurveillence and antitumor immunity. As such, regulation of these cellular functions with antibodies against CTLA-4 antibodies would provide an attractive alternative to CRC treatment. Another strategy would be to block lymphocytes recruitment to mucosal layer of the colon by FTY720, prodrug of FTY720-P that binds to S1P 1 . Prolonged exposure of the cells to FTY720-P prevents the recycling of S1P 1 to the surface after internalization. Hence, S1P signaling is blocked in the presence of FTY720 and FTY720-P. S1P pathway is unique in that it is not only involved in lymphocyte egression, but also that its intracellular signaling regulates the differentiation of CD4+ T cells into one type of immune cells that favor adaptive immunity, or another type (Tregs) that dampens it. The S1P pathway is also a critical component of the interaction between colon cancer cells and stromal cells. The IL-6/STAT3/SphK/S1P pathway promotes the persistent activation of STAT3 in tumors, which upregulates S1P to recruit immune cells which secrete IL-6. Thus, the development of Treg-centric therapeutics with S1P signaling inhibitor is likely to affect multiple cells and would add a novel and more effective therapeutic strategy against colorectal cancer especially those cancers associated with inflammation.
